Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

• Status: Completed
• Trial end date: 2020-08-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung origin

• No history of and no active symptoms related to carcinoid syndrome

• In addition to treatment-naive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT were allowed into the study. Pretreated patients had to have progressed on or after the last treatment

• Radiological documented disease progression within 6 months prior to randomization

• Measurable disease

• WHO performance status ≤1

• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma and small cell carcinoma

• Patients with pancreatic NET or NET of origins other than GI or Lung

• Patients with history of or active symptoms of carcinoid syndrome (e.g. flushing, diarrhea)

• Patients with more than one line of prior chemotherapy

• Prior targeted therapy

• Hepatic intra-arterial embolization within the last 6 months. Cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization

• Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus)

• Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

• Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

• Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy

• Patients who had any severe and/or uncontrolled medical conditions such as:

• unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to randomization, serious uncontrolled cardiac arrhythmia

• active or uncontrolled severe infection

• liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)

• Chronic treatment with corticosteroids or other immunosuppressive agents

• Known history of HIV seropositivity

• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria might apply.